New 'Living Drug' tested for Tough-to-Treat blood cancer
NCT ID NCT07336823
Summary
This is a very early study to check the safety and first signs of effectiveness of a new treatment called JY232 injection for people with multiple myeloma that has come back or stopped responding to other therapies. JY232 is a type of CAR-T cell therapy, where a patient's own immune cells are modified to fight the cancer. Up to 9 participants will receive the treatment and be closely monitored for up to two years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Foshan First People's Hospital
RECRUITINGFoshan, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.